Please assess the completion status of the following clinical trial:

Trial Title: Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 16 years of age or older~* Disease history of at least six months meeting at least 4 out of the 11 American College of Rheumatology (ACR) criteria for SLE~* Active SLE with at least one British Isles Lupus Assessment Group (BILAG) flare A or B at screening requiring a change in the dose of corticosteroids~* Positive antinuclear antibody (ANA) or anti-double-stranded deoxyribonucleic acid (dsDNA) at screening~* Female subjects must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks prior to Study Day 1, during the trial and 24 weeks after the last dose of study medication~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Active moderate to severe glomerulonephritis (kidney impairment) as defined in the protocol~* Active central nervous system SLE deemed to be severe/progressive and/or associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol~* Previous treatment with rituximab, abatacept, or belimumab~* History of demyelinating disease such as multiple sclerosis (MS) or optic neuritis~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atacicept 75 mg (Type: EXPERIMENTAL): None
- Atacicept 150 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).